Guillermo Garcia-Manero

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. Garcia Manero G, Scott B, Cogle C, Boyd T, Kambhampati S, Hetzer J, et al. CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia. Leuk Res. 2018;72:79-85 pubmed publisher
    ..Extended CC-486 dosing was generally well tolerated and induced hematologic responses in these patients regardless of pretreatment thrombocytopenia. ..
  2. Garcia Manero G, Assouline S, Cortes J, Estrov Z, Kantarjian H, Yang H, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008;112:981-9 pubmed publisher
    ..In summary, MGCD0103 was safe and had antileukemia activity that was mechanism based in patients with advanced leukemia. ..
  3. Yalniz F, Daver N, Rezvani K, Kornblau S, Ohanian M, Borthakur G, et al. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2018;: pubmed publisher
    ..Lirilumab either as a single agent as well as used in combination with azacitidine has clinical activity in patients with MDS. Further studies are needed to confirm our findings. ..
  4. DiNardo C, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, et al. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015;2:e12-20 pubmed publisher
    ..MD Anderson Cancer Center and Celgene. ..
  5. Cabrero M, Jabbour E, Ravandi F, Bohannan Z, Pierce S, Kantarjian H, et al. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leuk Res. 2015;39:520-4 pubmed publisher
    ..046). According to these results and considering the poor prognosis after HMA failure, HMA interruption should be avoided once a sustained response has been achieved. ..
  6. Benton C, Nazha A, Pemmaraju N, Garcia Manero G. Chronic myelomonocytic leukemia: Forefront of the field in 2015. Crit Rev Oncol Hematol. 2015;95:222-42 pubmed publisher
    ..Finally, we focus on available treatment strategies, with a special emphasis on experimental and forthcoming therapies. ..
  7. Garcia Manero G. Prognosis of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2010;2010:330-7 pubmed publisher
    ..This review summarizes current prognostic models of MDS and new molecular alterations with potential prognostic potential. ..
  8. Badar T, Patel K, Thompson P, Dinardo C, Takahashi K, Cabrero M, et al. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res. 2015;39:1367-74 pubmed publisher
    ..08, 95% confidence interval [CI]: 1.9-5.0, p<0.0001). In multivariate analysis, FLT3-ITD and RAS mutations had independent prognostic significance for poor outcome. ..
  9. Sanford D, DiNardo C, Tang G, Cortes J, Verstovsek S, Jabbour E, et al. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival. Clin Lymphoma Myeloma Leuk. 2015;15:556-62 pubmed publisher
    ..In our series, this was associated with a poor prognosis with a poor response to treatment, disease transformation to acute myeloid leukemia, and short overall survival. ..

More Information

Publications25

  1. Garcia Manero G. Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy. Best Pract Res Clin Haematol. 2012;25:427-35 pubmed publisher
    ..Here, we present the rationale for such combination and the studies that led to the support of this concept including both in vitro models and initial phase 1 trials. ..
  2. Garcia Manero G, Tibes R, Kadia T, Kantarjian H, Arellano M, Knight E, et al. Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Invest New Drugs. 2015;33:870-80 pubmed publisher
    ..Ilorasertib exhibited acceptable safety and pharmacokinetics at or below the recommended phase 2 dose, displayed evidence of dual Aurora kinase and VEGF receptor kinase inhibition, and activity in AML. ..
  3. Garcia Manero G, Khoury H, Jabbour E, Lancet J, Winski S, Cable L, et al. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res. 2015;21:985-94 pubmed publisher
    ..ARRY-614 was well tolerated and has sufficient activity to warrant further evaluation in this patient population. We recommend 1,200 mg once daily as the optimal dose for further study. ..
  4. Garcia Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol. 2011;29:516-23 pubmed publisher
  5. Ok C, Patel K, Garcia Manero G, Routbort M, Peng J, Tang G, et al. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015;8:45 pubmed publisher
    ..t-MN carrying TP53 mutation have an aggressive clinical course independent of other confounding factors. ..
  6. Garcia Manero G, Fenaux P, Al Kali A, Baer M, Sekeres M, Roboz G, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:496-508 pubmed publisher
    ..Onconova Therapeutics, Leukemia & Lymphoma Society. ..
  7. Cabrero M, Wei Y, Yang H, Ganan Gomez I, Bohannan Z, Colla S, et al. Down-regulation of EZH2 expression in myelodysplastic syndromes. Leuk Res. 2016;44:1-7 pubmed publisher
    ..Taken together, these data indicate that EZH2 underexpression may have unique impact on the molecular pathogenesis and prognosis in MDS and be an important marker for patients without chromosome 7 alteration. ..
  8. Yang H, Fang Z, Wei Y, Bohannan Z, Gañán Gómez I, Pierola A, et al. Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia. Leuk Res. 2017;59:85-92 pubmed publisher
    ..FF-10501-01 effectively induces AML cell death and reduces AML peripheral blood cell proliferation by targeting guanine nucleotide biosynthesis regardless of HMA resistance status. ..
  9. Garcia Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol. 2008;20:705-10 pubmed publisher
    ..Further work in new combination therapies may result in further advances in the care of patients with MDS. ..
  10. request reprint
    Garcia Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22:538-43 pubmed
    ..2 months (95% CI 13-18). In summary, this analysis indicates that it is possible to identify patients with lower risk MDS and poor prognosis who may benefit from early intervention. ..
  11. Chamseddine A, Jabbour E, Kantarjian H, Bohannan Z, Garcia Manero G. Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions. Curr Oncol Rep. 2016;18:4 pubmed publisher
    ..Here, we discuss new insights into diagnostic accuracy, prognostic assessment, pathogenic mechanisms, and effective treatments for MDS. ..
  12. Lyons R, Marek B, Paley C, Esposito J, McNamara K, Richards P, et al. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years. Leuk Res. 2017;56:88-95 pubmed publisher
  13. Garcia Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, et al. Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013;31:2548-53 pubmed publisher
    ..This open-label, randomized phase II trial assessed efficacy and tolerability of two low-dose regimens of subcutaneous (SC) decitabine in patients with low- or intermediate-1-risk myelodysplastic syndrome (MDS)...
  14. Garcia Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87:692-701 pubmed publisher
    ..MDS occurs more frequently in older male and in individuals with prior exposure to cytotoxic therapy...
  15. Garcia Manero G, Tambaro F, Bekele N, Yang H, Ravandi F, Jabbour E, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol. 2012;30:2204-10 pubmed publisher
    ..To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS)...
  16. Garcia Manero G, Gore S, Cogle C, Ward R, Shi T, Macbeth K, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 2011;29:2521-7 pubmed publisher